View up-to-date information on Arrowhead Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
AU2016331084B2 | Grant | Compositions and methods for inhibiting gene expression of LPA | A61K31/7088; A61P1/16; A61P43/00; A61P9/00; C12N15/113; C12N15/1137; C12N2310/14; C12N2310/31; C12N2310/315; C12N2310/321; C12N2310/351; C12N2310/3517; C12Y304/21 | September 08, 2022 |
EP4051798A1 | Application | RNAI-MITTEL ZUM HEMMEN DER EXPRESSION VON BETA-ENAC, ZUSAMMENSETZUNGEN DAVON UND VERFAHREN ZUR VERWENDUNG | A61K31/7105; A61K45/06; A61K47/545; C12N15/1138; C12N2310/14; C12N2310/315; C12N2310/317; C12N2310/321; C12N2310/322; C12N2310/343; C12N2310/3515 | September 07, 2022 |
KR1020220119522A | Application | B Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus | A61K2300/00; A61K31/713; A61P1/16; A61P29/00; A61P31/12; A61P31/20; A61P35/00; C12N15/11; C12N15/1131; C12N2310/14; C12N2310/315; C12N2310/321; C12N2310/335; C12N2310/351; C12N2310/3521 | August 29, 2022 |
AU2022206748A1 | Application | Compositions and methods for inhibiting gene expression of Hepatitis B virus | A61K2300/00; A61K31/713; A61P1/16; A61P29/00; A61P31/12; A61P31/20; A61P35/00; C12N15/11; C12N15/1131; C12N2310/14; C12N2310/315; C12N2310/321; C12N2310/335; C12N2310/351; C12N2310/3521; Y02A50/30 | August 18, 2022 |
KR102434357B1 | Grant | B Compositions and Methods for Inhibiting Gene Expression of Hepatitis B Virus | A61K2300/00; A61K31/713; A61P1/16; A61P29/00; A61P31/12; A61P31/20; A61P35/00; C12N15/11; C12N15/1131; C12N2310/14; C12N2310/315; C12N2310/321; C12N2310/335; C12N2310/351; C12N2310/3521 | August 18, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer